In Africa, many cancer-risk genes are old and have been around for a long time; outside Africa, many of those genes changed into a safer version, which is why non-African populations have lower risk.
Scientific Claim
Prostate cancer risk alleles are more likely to be ancestral (shared with primates) in African populations and derived (new mutations) in non-African populations, suggesting that evolutionary loss of protective alleles outside Africa contributed to lower risk.
Original Statement
“Fig. 2 reveals that risk allele frequencies tend to be higher in Africa when risk alleles are ancestral, and risk allele frequencies tend to be higher in non-African populations when risk alleles are derived (p-value = 0.0005, Fisher’s exact test).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim is based on statistical analysis of ancestral state inference from dbSNP and 1000 Genomes data. The use of 'tend to be' and the reported p-value appropriately reflect the correlational nature of the observation.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Ancient DNA Cohort StudyLevel 2aWhether the ancestral state of prostate cancer risk alleles was indeed more common in pre-migration African populations and became rarer in early Eurasian populations.
Whether the ancestral state of prostate cancer risk alleles was indeed more common in pre-migration African populations and became rarer in early Eurasian populations.
What This Would Prove
Whether the ancestral state of prostate cancer risk alleles was indeed more common in pre-migration African populations and became rarer in early Eurasian populations.
Ideal Study Design
Analysis of 100 ancient human genomes (pre- and post-out-of-Africa) from Africa, the Levant, and Europe, with targeted genotyping of the 68 prostate cancer SNPs to determine ancestral/derived status and frequency changes over time.
Limitation: Extremely limited ancient DNA availability from key time periods and regions.
Case-Control StudyLevel 3aWhether individuals carrying ancestral vs. derived alleles at these SNPs have different prostate cancer risk within African descent populations.
Whether individuals carrying ancestral vs. derived alleles at these SNPs have different prostate cancer risk within African descent populations.
What This Would Prove
Whether individuals carrying ancestral vs. derived alleles at these SNPs have different prostate cancer risk within African descent populations.
Ideal Study Design
A case-control study of 5,000 African descent men with prostate cancer and 5,000 controls, stratifying by ancestral/derived status of each risk allele and testing for association with cancer diagnosis and aggressiveness.
Limitation: Cannot determine whether the ancestral state caused higher risk or was merely preserved.
Systematic Review & Meta-AnalysisLevel 1aWhether the pattern of ancestral risk alleles being more common in Africa is consistent across other complex diseases with similar evolutionary histories.
Whether the pattern of ancestral risk alleles being more common in Africa is consistent across other complex diseases with similar evolutionary histories.
What This Would Prove
Whether the pattern of ancestral risk alleles being more common in Africa is consistent across other complex diseases with similar evolutionary histories.
Ideal Study Design
Meta-analysis of 50+ GWAS for complex diseases (e.g., diabetes, hypertension) testing whether risk alleles are more often ancestral in African populations and derived in non-African populations, compared to neutral SNPs.
Limitation: Cannot prove causality or mechanism—only identifies a pattern across diseases.
Functional Genomics AssayLevel 5Whether ancestral vs. derived alleles at these SNPs have different regulatory effects on gene expression in prostate cells.
Whether ancestral vs. derived alleles at these SNPs have different regulatory effects on gene expression in prostate cells.
What This Would Prove
Whether ancestral vs. derived alleles at these SNPs have different regulatory effects on gene expression in prostate cells.
Ideal Study Design
Dual-luciferase reporter assays comparing ancestral and derived alleles of rs9623117, rs6983267, etc., in prostate epithelial cell lines, measuring enhancer activity and transcription factor binding affinity.
Limitation: Does not reflect population-level selection or evolutionary history.
Transgenic Animal ModelLevel 4Whether introducing ancestral vs. derived alleles into mice alters prostate cancer susceptibility.
Whether introducing ancestral vs. derived alleles into mice alters prostate cancer susceptibility.
What This Would Prove
Whether introducing ancestral vs. derived alleles into mice alters prostate cancer susceptibility.
Ideal Study Design
Generation of two transgenic mouse lines: one carrying the human ancestral risk allele, one the derived protective allele, at the orthologous locus, with prostate tumor development monitored after carcinogen exposure.
Limitation: Mouse prostate biology differs significantly from human; evolutionary context is lost.
Evidence from Studies
Supporting (1)
Genetic Hitchhiking and Population Bottlenecks Contribute to Prostate Cancer Disparities in Men of African Descent.
The study found that Black men have higher prostate cancer risk because they inherited older genetic variants from Africa, while other populations got new genetic changes that lowered their risk—like evolution accidentally protecting some groups more than others.